EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study

F Huguet, A Guerci-Bresler, G Roth-Guepin, E Cayssials iD, B Slama, A Santagostino, A Penot, P Quittet, P Cony-Makhoul, A Saad, J N Bastie, M Hacini und 11 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19819 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von F Huguet und 22 weiteren Autor:innen. Beteiligte Einrichtung: Haematology Department, Cancer University Institute, University Hospital, Toulouse, France. Hauptthemen laut MEDLINE: Imidazoles, Pyridazines, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Incyte Biosciences France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The TOPASE study was set up to evaluate the outcomes of chronic myeloid leukaemia [CML] patients treated with ponatinib (PON) in a real‐world setting in France. One hundred and twenty CML patients, 105 in chronic phase (CP), 8 in accelerated phase (AP) and 7 in blastic phase (BP) were included. Fifty‐one (49%) of the CP‐CML patients were in third line of treatment. The trigger for PON initiation in CP‐CML was ‘poor response’ in 67 patients, ‘poor tolerance’ in 28 patients and ‘response enhancement’ in seven patients. The median dose at initiation was 30 mg/day [Q1; Q3 = 15; 30] in CP‐CML and 45 mg/day [Q1; Q3 = 30; 45] in AP/BP‐CML. Of 98 CP‐CML evaluable patients, 72 (73.5%) were considered as responders (MMR) at one time point at least once, especially for those in second line of treatment and/or presenting a T315I mutation. Ninety‐six of 120 (80%) patients reported at least one adverse event. An arterial occlusive event (AOE) was reported in 11 patients (9.2%). Thus, these real‐life data confirm the potency of ponatinib in resistant or intolerant patients with an acceptable safety profile in non‐selected patients. NCT number : NCT04048564.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImidazolesPyridazinesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansFemaleMaleMiddle AgedFranceAgedAdultTreatment OutcomeAged, 80 and overProtein Kinase InhibitorsAntineoplastic Agents

Stichwörter der Autor:innen

CMLTKIponatinibreal‐life setting

Substanzen

ponatinibImidazolesPyridazinesProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Haematology Department, Cancer University Institute, University Hospital, Toulouse, France.
  • Fi LMC Centre Léon Bérard, Lyon, France.
  • Haematology Department, Regional University Hospital Brabois, Vandoeuvre-les-Nancy, France.
  • Haematoloy and Cellular Therapy Department, University Hospital, Poitiers, France.
  • CIC INSERM 1402, Poitiers, France.
  • Hospital Centre, Avignon, France.

ORCID-Profile: E Cayssials, L Roy, M Berger, G Etienne, F E Nicolini

Förderung

  • Incyte Biosciences France

Zitieren

APA

Huguet, F., Guerci-Bresler, A., Roth-Guepin, G., Cayssials, E., Slama, B., Santagostino, A., Penot, A., Quittet, P., Cony-Makhoul, P., Saad, A., Bastie, J. N., Hacini, M., Coiteux, V., Uzunov, M., Roy, L., Le Clech, L., Berger, M., Agneray, A. M., Messas, E., …, & Rousselot, P. (2024). Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study. British Journal of Haematology. https://doi.org/10.1111/bjh.19819

Vancouver

Huguet F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, Slama B, Santagostino A, et al. Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study. British Journal of Haematology. 2024. doi:10.1111/bjh.19819

BibTeX
@article{Huguet2024,
  author = {Huguet, F and Guerci-Bresler, A and Roth-Guepin, G and Cayssials, E and Slama, B and Santagostino, A and Penot, A and Quittet, P and Cony-Makhoul, P and Saad, A and Bastie, J N and Hacini, M and Coiteux, V and Uzunov, M and Roy, L and Le Clech, L and Berger, M and Agneray, A M and Messas, E and Etienne, G and Turhan, A and Nicolini, F E and Rousselot, P},
  title = {Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19819}
}
Kostenlos starten →